Entera Bio Ltd. (ENTX) – What Are Brokerages Saying About This Stock?

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) has received an average rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.60.

Several research firms have weighed in on ENTX. Lifesci Capital initiated coverage on Entera Bio in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target for the company. Leerink Partners initiated coverage on shares of Entera Bio in a research report on Friday, September 18th. They set an “outperform” rating and a $9.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Entera Bio in a report on Tuesday, September 22nd. They issued an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, October 15th. Finally, UBS Group set a $9.00 target price on shares of Entera Bio in a research report on Friday, September 18th.

Read Our Latest Report on Entera Bio

Institutional Trading of Entera Bio

Hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. purchased a new position in shares of Entera Bio during the third quarter valued at about $14,265,000. Logos Global Management LP bought a new stake in shares of Entera Bio in the third quarter worth about $12,838,000. Nantahala Capital Management LLC purchased a new stake in shares of Entera Bio in the third quarter worth about $8,744,000. Renaissance Technologies LLC lifted its position in shares of Entera Bio by 338.4% in the first quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock worth $526,000 after buying an additional 365,441 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Entera Bio in the third quarter worth about $613,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Stock Up 0.6%

NASDAQ ENTX opened at $3.28 on Friday. The firm has a market cap of $571.18 million, a price-to-earnings ratio of -8.41 and a beta of 1.48. The business has a 50-day moving average price of $2.92 and a 200-day moving average price of $2.02. Entera Bio has a twelve month low of $0.91 and a twelve month high of $4.20.

Entera Bio (NASDAQ:ENTX – Get Free Report) last released its earnings results on Friday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Research analysts expect that Entera Bio will post -0.40 EPS for the current fiscal year.

Entera Bio Company Profile

(Get Free Report)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.

Featured Stories

Analyst Recommendations for Entera Bio (NASDAQ:ENTX)

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.